HomeCompareTTNP vs ORCC

TTNP vs ORCC: Dividend Comparison 2026

TTNP yields 85.47% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TTNP wins by $2.09M in total portfolio value
10 years
TTNP
TTNP
● Live price
85.47%
Share price
$2.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.11M
Annual income
$639,398.81
Full TTNP calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — TTNP vs ORCC

📍 TTNP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTNPORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTNP + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTNP pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTNP
Annual income on $10K today (after 15% tax)
$7,264.96/yr
After 10yr DRIP, annual income (after tax)
$543,488.99/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, TTNP beats the other by $543,488.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTNP + ORCC for your $10,000?

TTNP: 50%ORCC: 50%
100% ORCC50/50100% TTNP
Portfolio after 10yr
$1.07M
Annual income
$319,699.92/yr
Blended yield
29.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

TTNP
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-240.6
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTNP buys
0
ORCC buys
0
No recent congressional trades found for TTNP or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTNPORCC
Forward yield85.47%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$2.11M$21.4K
Annual income after 10y$639,398.81$1.04
Total dividends collected$1.85M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: TTNP vs ORCC ($10,000, DRIP)

YearTTNP PortfolioTTNP Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$19,247$8,547.01$11,190$489.61+$8.1KTTNP
2$35,969$15,374.24$12,229$256.01+$23.7KTTNP
3$65,338$26,851.55$13,216$130.74+$52.1KTTNP
4$115,497$45,585.62$14,207$66.02+$101.3KTTNP
5$198,892$75,309.60$15,234$33.17+$183.7KTTNP
6$334,016$121,202.50$16,317$16.62+$317.7KTTNP
7$547,628$190,230.15$17,468$8.32+$530.2KTTNP
8$877,445$291,482.95$18,695$4.16+$858.8KTTNP
9$1,375,345$436,479.30$20,006$2.08+$1.36MTTNP
10$2,111,018$639,398.81$21,407$1.04+$2.09MTTNP

TTNP vs ORCC: Complete Analysis 2026

TTNPStock

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Full TTNP Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this TTNP vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTNP vs SCHDTTNP vs JEPITTNP vs OTTNP vs KOTTNP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.